Company Story:

Oxford MEStar Limited is a spin-out company from the Institute of Biomedical Engineering of Oxford University specializing in translational and regenerative medicine. The company is devoted to a) developing novel technologies; b) offering bioengineering solutions to their clients; and c) technology transfer between the UK and China.

In December 2013 Oxford MEStar received £1M investment and another £1.1M in July 2015 from the private sector, and was awarded funding to take part in a 36-month, € 6.84 Million project under the European Union Interreg 2 Seas initiative that will support development and streamlined integration of 3D printing technologies to enable advanced medical treatment and its widespread application.


  • Develops enabling technologies for tissue engineering and stem cell therapy
  • Measure Bowel Health, the first and only digital at-home testing kit for the detection of invisible traces of blood in stool
  • 3D printing services such as OMEFlex™️ and PetAssist™️


Joint Project Title

Joint research and usability tests in Turkey measuring bowel health

Partnership by

🇹🇷 Nanobiz

🇬🇧 Oxford MEStar

View Details

Company Info:

Establishment Date:

October 28, 2013

Number of Employees:



Biotechnology, in-vitro diagnostics, technology transfer


Explore more companies:

Supported by